Events

We invite all of our shareholders to attend our annual meeting, scheduled for Monday June 18th at the Westin Cleveland Hotel, located at 777 St. Clair Ave NE in Cleveland. A continental breakfast will be served at 11 AM and the meeting will follow at 11:30 AM.

Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7^th, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Laura Campbell, Senior Vice President of Finance and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 7396506

Athersys will be attending the JP Morgan Healthcare conference, where companies gather to share exciting advances that are driving medical #innovation to help transform clinical care for patients.

Thank you to everyone that attended the event. To view a highlight video of the event, please fill out this form. Your name and a valid email address is required for viewing.

Registration opens at 7:30 AM EDT

Advanced registration is required, please register here: https://www.athersys.com/investors/resources/annual-information/default.aspx

BlueRock Therapeutics Ballroom

For more information, please click here.

Clinical Development of MultiStem(R) Therapies

For more information: please click here.

January 21, 2020

10:45 a.m.
Treatment of Acute Clinical Indications with Cell Therapy
by Anthony Ting, PhD, VP of Regenerative Medicine, Athersys, Inc.

January 22, 2020

9:15 a.m.
Panel Discussion: Recent Advances on RMAT and TRIP
by Robert W. Mays, VP of Regenerative Medicine and Head of Neuroscience Programs, Athersys, Inc.

January 24, 2020

9:05 a.m.
Clinical Development of MultiStem, an Adult Stem Cell Therapy for Treatment of Acute Injuries of the Central Nervous System
by Robert W. Mays, VP of Regenerative Medicine and Head of Neuroscience Programs, Athersys, Inc.

Cell Therapy Treatments for COVID-19

Thursday, May 21, 2020 at 11 AM EST

This webinar will highlight potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, will present on their treatment approaches and plans for near term clinical trials.

Speakers:

Eric Jenkins, M.D., Senior Medical Director and Head of Clinical Operations, Athersys

Dr. Jenkins rejoined Athersys as Medical Director in 2016, where he is responsible for medical oversight of all clinical development activities. With 20 years of clinical experience, he contributes medical expertise to the Company’s long-term strategic planning and serves as the medically-informed voice for external communications with clinical investigators, regulators, key opinion-leaders and patient communities. In addition, Dr. Jenkins currently leads the pure-commercial medical affairs activities, including preparation for market access, coding and reimbursement for MultiSteam cell therapy products following approval.

Racheli Ofir, Ph.D., Vice President Research and Intellectual Property, Pluristem Therapeutics

Dr. Ofir joined Pluristem in 2007, as Vice President of research and intellectual property. The Research Department examines the various cells developed by the company, the properties of those cells and their mechanisms of action by using molecular methods and animal models to test the safety and efficacy. The IP department is responsible for intellectual property strategy development as well as the research that supports the IP. Dr. Ofir is responsible for leading projects involving the characterization of PLX cells, Pluristem’s leading placenta derived cell product candidate, including evaluating the biological activity of the cells in in-vitro and animal studies. She is responsible for the studies which determines the safety profile and pharmacokinetics of PLX cells.

RSVP to listen the free webinar here.

Welcome to the 2020 Annual Meeting of Stockholders (the “Annual Meeting”) of Athersys, Inc. (“Athersys”). This year our Annual Meeting is taking place in a virtual-only format. 

Only stockholders as of the close of business on Friday, April 24, 2020 (the “Record Date”) or holders of proxies may participate, vote or ask questions at the Annual Meeting. To gain access to the Annual Meeting, you will need the 16-digit control number located on your proxy card. Please keep your control number in a safe place so it is available to you for the meeting. Using this control number, you will be able to participate in the live meeting. Please allow ample time for online check-in, which will begin at 8:15 a.m., Eastern Daylight Time, on June 18, 2020. If you do not have a control number, please contact your broker ahead of time to obtain it.

Agenda

1. Call Meeting to Order by Gil Van Bokkelen, Chief Executive Officer and Chairman of the Board of Directors of Athersys, Inc.

2. Introduction of Directors, Director Nominee and Officers.

3. Introduction of Independent Registered Public Accounting Firm.

4. Report by Secretary of Mailing.

5. Presentation of List of Stockholders as of Record Date.

6. Report of Quorum by the Inspector of the Election.

7. Nomination and Election of Directors.

8. Ratify Appointment of Independent Auditor.

9. Approve, on an Advisory Basis, Named Executive Officer Compensation.

10. Report of the Inspector of the Election.

11. Other and Further Business and Adjournment.

12. General Question and Answer Period.

Rules of Conduct

In fairness to all stockholders and in the interest of an orderly and constructive meeting, the following procedures will apply:

1. This virtual Annual Meeting of the stockholders of Athersys will follow the order on the agenda.  You need to have held stock as of the close of business on the record date of April 24, 2020 to participate, vote or submit questions while participating in the Annual Meeting. 

2. To access the Annual Meeting, you will need to enter the 16-digit control number you received with your proxy materials and may enter the meeting starting at 8:15 AM ET on June 18, 2020.  If you have voted your shares prior to the start of the Annual Meeting by proxy or via the internet or telephone, your vote has been received by Athersys’ Inspector of Elections and there is no need to vote those shares during the Annual Meeting, unless you wish to revoke or change your vote.  

3. During the business portion of the Annual Meeting, all comments should be limited to the relevant agenda items. To submit your comment, type your comment along with your full name, and if applicable, the specific proposal to which your comment relates in the “Ask a Question” field, and click “Submit.” In order to facilitate responses and discussion, all comments should be succinct and limited to one topic. Others will not see your name or your comment, and we will not reveal your identity.

4. After the business portion of the Annual Meeting has been adjourned, a general update and “Question and Answer” period will follow. Such questions may be submitted in the field provided in the web portal during the Annual Meeting. Please provide your full name along with your question.

5. To allow as many stockholders as possible the opportunity to be heard, each stockholder will be permitted no more than two questions.

6. Questions from multiple shareholders on the same topic or that are otherwise related may be grouped, summarized and answered together.

7. Athersys does not intend to answer questions that are, among other things:

• Irrelevant to the business of Athersys or to the business of the meeting;

• Related to material non-public information of Athersys;

• Related to personal grievances;

• Derogatory references to individuals or that are otherwise in bad taste;

• Related to threatened or ongoing legal action or litigation;

• Repetitious statements already made by another shareholder;

• In furtherance of the shareholder’s personal or business interests; or

• Out of order or not otherwise suitable for the conduct of the meeting as determined by the Chairman or Corporate Secretary in their reasonable judgment.

8. Individual concerns. If there are any matters of individual concern to a shareholder and not of general concern to all shareholders, or if a question posed was not otherwise answered due to time restraints, such matters or questions may be raised separately after the meeting by contacting Investor Relations at ir@athersys.com.

9. In the event of disorder, technical malfunction or other significant problem that disrupts the meeting, the Chairman may adjourn, recess or expedite the meeting or take such other action that the Chairman determines is appropriate in light of the circumstances. In such case, please stay connected to the meeting website for at least 15 minutes. If the meeting cannot be resumed, (i) all items of the official business of the meeting described in the proxy statement will be deemed to be properly before the meeting; (ii) all proxy and other votes received before the start of the interruption will be deemed to have been validly cast; and (iii) the official business of the meeting will be deemed to have been validly completed and the meeting adjourned immediately thereafter.

10. No one attending via the webcast is permitted to use any audio or recording device. 

11. Copying of materials presented at the meeting is prohibited, including screenshots.

12. Forward Looking Statements. We may make forward-looking statements during the Annual Meeting, which are subject to various risks and uncertainties. Please see the Athersys filings with the Securities and Exchange Commission (SEC) for more information on the risks that could cause our actual results to differ from these forward-looking statements.

The violation of any of these rules will be considered cause for expulsion from the meeting.

Thank you for your cooperation and participation.

Dr. Anthony Ting will be participating in a panel discussion at the Virtual Cell and Gene Meeting on the Mesa. This event requires a paid registration to view the webcast.  To register for the meeting, please visit the registration site.

OVERCOMING CHALLENGES WITH THE DEVELOPMENT AND TRANSLATION OF A THERAPEUTIC FROM ACADEMIA TO INDUSTRY

Some of the most cutting-edge and innovative approaches to cell and gene therapy have originated from the academic setting. However, getting these treatments into the clinic can be especially challenging when the institution does not have the experience and infrastructure necessary to conduct preclinical studies, manufacture to GMP standards, and file regulatory submissions with the FDA. This panel of experts will discuss their lessons learned throughout the process and best approaches to moving a cell and gene therapeutic candidate from academia to commercialization.

Chair:

Shawn Roach, Ph.D., Specialist-Regulatory CMC, Halloran Consulting Group

Speakers:

Isabelle Riviere, Ph.D., Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
Anthony Ting, Ph.D., VP of Regenerative Medicine and Head of Cardiopulmonary Programs, Athersys

Please join us for an informational webinar for ARDS ICU patients, survivors and families  Hear from leading clinicians from The Cleveland Clinic and from ARDS patient survivors. This virtual webinar will educate patients and doctors about COVID-19, ARDS and post-ICU recovery.

 Speakers Include:

• Eileen Rubin, President of the ARDS Foundation
• Dr. Michelle Biehl, Medical Director, Cleveland Clinic Post-ICU Recovery Clinic
• Dr. Josh Veith, Critical care physician and pulmonologist at Cleveland Clinic
• Panel discussion with Drs. Michelle Biehl, Eileen Bishop, Karna Sarin and Joshua Veith of the Cleveland Clinic
• ARDS patient survivor testimonials

 This event is being hosted by the ARDS Foundation and The Cleveland Clinic and is sponsored by Athersys.

To view the presentation Click here

The 2021 Annual Meeting will be a virtual meeting and stockholders of the record date 4/23/2021 may participate online at http://www.virtualshareholdermeeting.com/ATHX2021 on June 15, 2021 at 8:30 AM Eastern Daylight Time.

To attend the Annual Meeting, you will need the 16-digit control number located on your proxy card. If you do not have your control number, please reach out to your broker to attain it. Please keep your control number in a safe place so it is available to you for the meeting. Please allow ample time for online check-in, which will begin at 8:15 AM EDT.

Dr. Robert (Willie) Mays, Vice President of Regenerative Medicine and Head of Neuroscience Programs will be participating in this year’s Cell & Gene Meeting on the Mesa by presenting the Athersys company presentation.

Presentation Date: Tuesday, October 12, 2021
Presentation Time: 6:00pm EST

William “B.J.” Lehmann, Interim CEO will be a also panelist at this year’s conference.

Panel Title: Personalizing Cardiovascular Therapies to Address the Underlying Causes of Disease
Panel Date: Wednesday, October 13, 2021
Panel Time: 6:15pm – 7:15pm EST
Panel Participants: 
Faraz Ali, CEO, Tenaya Therapeutics
Joachim Fruebis, Ph.D., Chief Development Officer, BlueRock Therapeutics
Jordan Lancaster, Ph.D., Co-founder and CEO, Avery Therapeutics
William “B.J.” Lehmann, Interim CEO, Athersys
Michael Scott, Vice President, Cell Therapy Medical Devices, Novo Nordisk
Monica Shah, M.D., Vice President and Head, Cell and Gene Therapy Center of Excellence, IQVIA.

Learn more and register for the event here. 

Athersys will be attending the JP Morgan 40th Annual Healthcare Conference.

We invite any investors and business partners interested in having a meeting with us to send an email to ir@athersys.com.

Manal Morsy, Senior VP & Head of Global Regulatory Affairs at Athersys, will be participating in the International Society for Cell & Gene Therapy Annual Meeting on Wednesday, May 4th in San Francisco, California. She'll join industry experts in two roundtable discussions titled "Global Market Strategies & Entering APAC Market" and "Innovative Cell and Gene Therapy Clinical Trial Design and Development Strategies to Enhance Inclusivity and Diversity".

Additionally, Rochelle Cutrone, Associate Scientist at Athersys, will be presenting a poster at ISCT titled "Multipotent adult progenitor cells modulate monocyte/macrophage phenotype, cytokine secretion and function".

More information is available on the conference here: https://www.isctglobal.org/isct2022/

Athersys will participate in person at the BofA Securities 2022 Healthcare Conference, which takes place from May 9-13 in Las Vegas, Nevada.

Dan Camardo, CEO, and Ivor Macleod, CFO, of Athersys will be participating in a fireside chat with a Bank of America analyst on Wednesday, May 11th at 4:00 p.m. PT/7:00 p.m. ET. The Company’s management team will also participate in one-on-one meetings with institutional investors during the conference.

A live webcast and replay of the event can be accessed here: https://bofa.veracast.com/webcasts/bofa/hc2022/id3qO151.cfm

The 2022 Annual Meeting will be a virtual meeting and stockholders of the record date 6/9/2022 may participate online at https://www.virtualshareholdermeeting.com/ATHX2022 on July 28, 2022 at 8:30 AM Eastern Daylight Time.

To attend the Annual Meeting, you will need the 16-digit control number located on your proxy card. If you do not have your control number, please reach out to your broker to attain it. Please keep your control number in a safe place so it is available to you for the meeting. Please allow ample time for online check-in, which will begin at 8:15 AM EDT.

Dr. Robert W. Mays, Executive Vice President and Head of Regenerative Medicine & Neuroscience, will present live at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, California on October 11 at 4:00 pm PT. Dr. Mays will provide a corporate overview of the Company’s therapeutic MultiStem® cellular therapy, and an update on preclinical and clinical perspectives utilizing the MultiStem cellular platform technology to date. The presentation will provide an overview of the Company’s ongoing clinical studies in ischemic stroke, acute respiratory distress syndrome and trauma.

Mr. Dan Camardo, Chief Executive Officer, Ms. Maia Hansen, Chief Operating Officer, and Dr. Sarah Busch, Vice President of Regenerative Medicine, will also be in attendance from October 11-13 to meet with registered attendees.

A live video webcast of all company presentations and sessions will be available for registered participants at http://www.meetingonthemesa.com and will also be published on the conference website after the event concludes. In addition, a webcast of the corporate presentation by Dr. Mays will be posted on the investor section of www.athersys.com when it becomes available. Please visit www.meetingonthemesa.com for detailed conference information and registration. 

Click here to register

Athersys will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company’s recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2.

In lieu of a live question and answer session, management encourages participants to submit questions in advance to ir@athersys.com. A replay of the event will be available under the Investors section on the Athersys website www.athersys.com.

Event Replay:
Toll Free Dial in Number: 1- 800- 770- 2030        
Toll Dial in Number: 1- 647- 362- 9199
Conference ID: 70781

This is a past event

Athersys hosted a business update conference call on August 9, 2023 at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, provided an overview of the Company’s recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke.

REPLAY INFORMATION

Toll Free Dial in Number: 1-800-770-2030
Toll Dial in Number: 1-647-362-9199
Conference ID: 70781
Encore Replay Dates: 08/09/2023 – 08/16/2023 23:59 ET